Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial (vol 385, 1087, 2015)

被引：0
|
作者：
Sulkowski, M.
Hezode, C.
Gerstoft, J.
机构：
来源：
LANCET | 2015年 / 385卷 / 9973期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1074 / 1074
页数：1
相关论文
共 50 条
  • [1] Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial
    Sulkowski, Mark
    Hezode, Christophe
    Gerstoft, Jan
    Vierling, John M.
    Mallolas, Josep
    Pol, Stanislas
    Kugelmas, Marcelo
    Murillo, Abel
    Weis, Nina
    Nahass, Ronald
    Shibolet, Oren
    Serfaty, Lawrence
    Bourliere, Marc
    Dejesus, Edwin
    Zuckerman, Eli
    Dutko, Frank
    Shaughnessy, Melissa
    Hwang, Peggy
    Howe, Anita Y. M.
    Wahl, Janice
    Robertson, Michael
    Barr, Eliav
    Haber, Barbara
    LANCET, 2015, 385 (9973): : 1087 - 1097
  • [2] Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial
    Lawitz, Eric
    Gane, Edward
    Pearlman, Brian
    Tam, Edward
    Ghesquiere, Wayne
    Guyader, Dominique
    Alric, Laurent
    Bronowicki, Jean-Pierre
    Lester, Laura
    Sievert, William
    Ghalib, Reem
    Balart, Luis
    Sund, Fredrik
    Lagging, Martin
    Dutko, Frank
    Shaughnessy, Melissa
    Hwang, Peggy
    Howe, Anita Y. M.
    Wahl, Janice
    Robertson, Michael
    Barr, Eliav
    Haber, Barbara
    LANCET, 2015, 385 (9973): : 1075 - 1086
  • [3] Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trial
    Rockstroh, Juergen K.
    Nelson, Mark
    Katlama, Christine
    Lalezari, Jay
    Mallolas, Josep
    Bloch, Mark
    Matthews, Gail V.
    Saag, Michael S.
    Zamor, Philippe J.
    Orkin, Chloe
    Gress, Jacqueline
    Klopfer, Stephanie
    Shaughnessy, Melissa
    Wahl, Janice
    Nguyen, Bach-Yen T.
    Barr, Eliav
    Platt, Heather L.
    Robertson, Michael N.
    Sulkowski, Mark
    LANCET HIV, 2015, 2 (08): : E319 - E327
  • [4] Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trial (vol 2, pg 319, 2015)
    Rockstroh, J. K.
    Nelson, M.
    Katlama, C.
    LANCET HIV, 2015, 2 (08): : E316 - E316
  • [5] Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trial (vol 2, pg e319, 2015)
    Rockstroh, J. K.
    Nelson, M.
    Katlama, C.
    LANCET HIV, 2015, 2 (10): : E416 - E416
  • [6] EFFICACY AND SAFETY OF MK-5172 AND MK-8742 ± RIBAVIRIN IN HEPATITIS C GENOTYPE 1 INFECTED PATIENTS WITH CIRRHOSIS OR PREVIOUS NULL-RESPONSE: THE C-WORTHY STUDY
    Lawitz, E.
    Hezode, C.
    Gane, E.
    Tam, E.
    Lagging, M.
    Balart, L.
    Rossaro, L.
    Ghalib, R.
    Shaughnessy, M.
    Hwang, P.
    Wahl, J.
    Robertson, M. N.
    Haber, B.
    JOURNAL OF HEPATOLOGY, 2014, 60 (01) : S25 - S26
  • [7] SAFETY AND EFFICACY OF THE ALL-ORAL REGIMEN OF MK-5172/MK-8742+RIBAVIRIN IN TREATMENT-NAIVE, NON-CIRRHOTIC, PATIENTS WITH HEPATITIS C VIRUS GENOTYPE 1 INFECTION: THE C-WORTHY STUDY
    Hezode, C.
    Serfaty, L.
    Vierling, J. M.
    Kugelmas, M.
    Pearlman, B.
    Sievert, W.
    Ghesquiere, W.
    Zuckerman, E.
    Sund, F.
    Shaughnessy, M.
    Hwang, P.
    Wahl, J.
    Robertson, M. N.
    Haber, B.
    JOURNAL OF HEPATOLOGY, 2014, 60 (01) : S5 - S5
  • [8] Efficacy and safety of MK-5172 and MK-8742 ± ribavirin in hepatitis C genotype 1 infected patients with cirrhosis or previous null response: Final results of the C-WORTHY Study (Parts A and B)
    Lawitz, Eric
    Gane, Edward J.
    Pearlman, Brian
    Tam, Edward
    Ghesquiere, Wayne
    Guyader, Dominique
    Alric, Laurent
    Bronowicki, Jean-Pierre
    Rossaro, Lorenzo
    Sievert, William
    Ghalib, Reem H.
    Balart, Luis A.
    Sund, Fredrik
    Lagging, Martin
    Dutko, Frank
    Howe, Anita Y.
    Shaughnessy, Melissa
    Hwang, Peggy
    Wahl, Janice
    Robertson, Michael
    Haber, Barbara A.
    HEPATOLOGY, 2014, 60 : 296A - 297A
  • [9] Efficacy, Safety And Pharmacokinetics Of Grazoprevir (MK-5172) And Elbasvir (MK-8742) In Hepatitis C Genotype 1 Infected Non-Cirrhotic Japanese Patients (Phase 2 Portion In Phase 2/3 Combined Study)
    Kawada, Norifumi
    Suzuki, Fumitaka
    Karino, Yoshiyasu
    Chayama, Kazuaki
    Itoh, Yoshito
    Okanoue, Takeshi
    Nakamuta, Makoto
    Yatsuzuka, Naoyoshi
    Fujimoto, Go
    Lupinacci, Lisa Chiacchierini
    Robertson, Michael
    Caro, Luzelena
    Tatosian, Daniel A.
    Howe, Anita Y.
    Kumada, Hiromitsu
    HEPATOLOGY, 2015, 62 : 559A - 559A
  • [10] Projected Long-Term Impact of Grazoprevir (GZR, MK-5172)/ Elbasvir (EBR, MK-8742) in Treatment-Naive and Treatment-Experienced Patients with Hepatitis C Virus Genotype 1 Infection and Chronic Kidney Disease
    Ferrante, Shannon A.
    Elbasha, Elamin
    Greaves, Wayne
    Nwankwo, Chizoba
    HEPATOLOGY, 2015, 62 : 571A - 572A
12345